Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC grew its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 24.9% during the fourth quarter, HoldingsChannel reports. The firm owned 72,600 shares of the biopharmaceutical company’s stock after purchasing an additional 14,485 shares during the quarter. Intra-Cellular Therapies comprises approximately 1.5% of Lisanti Capital Growth LLC’s portfolio, making the stock its 16th biggest holding. Lisanti Capital Growth LLC’s holdings in Intra-Cellular Therapies were worth $6,064,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Intra-Cellular Therapies by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock valued at $1,878,000 after purchasing an additional 2,157 shares during the period. Barclays PLC increased its holdings in shares of Intra-Cellular Therapies by 282.0% in the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock valued at $2,521,000 after purchasing an additional 25,435 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Intra-Cellular Therapies by 31.9% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company’s stock valued at $33,258,000 after purchasing an additional 109,892 shares during the period. Oak Ridge Investments LLC increased its holdings in shares of Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after purchasing an additional 8,440 shares during the period. Finally, Cynosure Group LLC increased its holdings in shares of Intra-Cellular Therapies by 161.0% in the third quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company’s stock valued at $1,057,000 after purchasing an additional 8,909 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Performance

ITCI opened at $131.25 on Friday. The business’s fifty day moving average is $118.27 and its two-hundred day moving average is $93.05. The company has a market cap of $13.96 billion, a price-to-earnings ratio of -150.86 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a one year low of $63.30 and a one year high of $131.36.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. On average, analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Analysts Set New Price Targets

ITCI has been the topic of a number of analyst reports. Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their price target for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Finally, Piper Sandler restated a “neutral” rating and issued a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Ten analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Intra-Cellular Therapies presently has an average rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.